New strategic collaboration leverages Sosei Heptares’ StaR® technology and SBDD platform and AbbVie’s extensive neuroscience expertise Second collaboration with AbbVie follows 2020 agreement focused on inflammatory and autoimmune diseasesSosei Heptares ...
Late-breaking data from the double-blind portion of the noninvasive Phase 3 MAESTRO NAFLD-1 study show resmetirom to be safe and well-tolerated and to reduce liver fat, fibrosis measures on FibroScan ...
New York, United States, June 16, 2022 (GLOBE NEWSWIRE) -- The scope of pharmaceutical logistics encompasses the activities of handling, transporting, and managing the supply chain for a wide variety of ...
According to Frost & Sullivan, digitalization across the pharmaceutical value chain will improve the industry´s efficiency. SAN ANTONIO, June 16, 2022 /PRNewswire/ -- Frost & Sullivan's recent analysis, Global Pharmaceuticals ...
Las Vegas, NV, June 08, 2022 (GLOBE NEWSWIRE) -- RedChip Companies will air a new C-Level interview with Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc. on ...
TEL AVIV, Israel, May 27, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat ...
SALT LAKE CITY, May 23, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or ...
TOKYO, Japan and CAMBRIDGE, United Kingdom, May 13, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results ...
CURE’s Patented and Proprietary OTF Vitamin D Found to be More Effective than Standard Supplementation in Achieving pre- and post-Surgery Vitamin D Sufficiency Necessary to Reduce Immune-Mediated Damage such as ...
Taiho obtains exclusive global rights to CLN-081/TAS6417 outside the U.S.; in the U.S., Taiho and Cullinan Oncology to jointly develop and co-commercialize CLN-081/TAS6417 Cullinan Oncology will receive an upfront cash ...
Copyright © 2015 - 2021 Lifecarenews.in
